Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: Therapeutic potential of resveratrol

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 3, 2008, Pages 961-968

  Aubin, Marie Claude ^a,c   Lajoie, Claude ^b   Clément, Robert ^c   Gosselin, Hugues ^c   Calderone, Angelino ^a,c,d   Perrault, Louis P ^a,c,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d Fonds de la Recherche en Sante du Quebec   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; LIPID; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART MUSCLE FIBROSIS; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LIPID DIET; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASCULAR DISEASE; VASCULAR RING; VASODILATATION; WEIGHT GAIN;

ACETYLCHOLINE; ANIMALS; ANTIOXIDANTS; AORTA; BLOOD PRESSURE; DIETARY FATS; FEMALE; FIBROSIS; HYPERLIPIDEMIAS; MYOCARDIUM; NITROPRUSSIDE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; VASODILATION; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 44249100660     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.135061     Document Type: Article

References (33)

1. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342.
2. Baur JA and Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506.
3. Berk BC, Fujiwara K, and Lehoux S (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117:568-575.
4. Calderone A, Takahashi N, Izzo NJ, Thaik CM, and Colucci WS (1995) Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation 92:2385-2390.
5. Carroll JF and Tyagi SC (2005) Extracellular matrix remodeling in the heart of the homocysteinemic obese rat. Am J Hypertens 18:692-698.
6. Das DK and Maulik N (2006) Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 6:36-47.
7. Dobrian AD, Davies MJ, Prewitt RL, and Lauterio TJ (2000) Development of hypertension in a rat model of diet-induced obesity. Hypertension 35:1009-1015.
8. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, and Prewitt RL (2001) Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 37:554-560.
9. Erdei N, Toth A, Pasztor ET, Papp Z, Edes I, Koller A, and Bagi Z (2006) High fat diet-induced reduction in nitric-oxide dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion. Am J Physiol Heart Circ Physiol 291:H2107-H2115.
10. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnel JP, Chade AR, Lerman LO, and Lerman A (2007) Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol 292:H904-H911.
11. Gehm BD, McAndrews JM, Chien PY, and Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 94:14138-14143.
12. Goto D, Fujii S, Zaman AK, Sakuma I, Gao M, Koyama T, Mitchell J, Woodcock-Mitchell J, Sobel BE, and Kitabatake A (1999) Long-term blockade of nitric oxide synthesis in rats modulates coronary network remodeling. Angiogenesis 3:137-146.
13. Grossman W, Jones D, and McLaurin LP (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56-64.
14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr., et al. (2006) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 21:1-6.
15. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, and Vasan RS (2002) Obesity and the risk of heart failure. N Engl J Med 347:305-313.
16. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, and Eckel RH (2004) Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110:2952-2967.
17. Lu Z, Xu X, Hu X, Zhu G, Zhang P, van Deel ED, French JP, Fassett JT, Tim D, Oury TD, et al. (2008) Extracellular superoxide dismutase deficiency exacerbates pressure overload-induced left ventricular hypertrophy and dysfunction. Hypertension 51:19-25.
18. Mercier I, Mader S, and Calderone A (2002a) Ovarian hormones induce TGF-β and fibronectin mRNAs but exhibit a disparate action on cardiac fibroblast proliferation. Cardiovasc Res 53:728-739.
19. A receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis. Br J Pharmacol 136:685-692.
20. Nishikawa S, Yasoshima A, Doi K, Nakayama H, and Uetsuka K (2007) Involvement of sex, strain and age factors in high fat diet-induced obesity in C57BL/6J and BALB/cA mice. Exp Anim 56:263-272.
21. Olson ER, Naugle JE, Zhang X, Bomser JA, and Meszaros JG (2005) Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 288:H1131-H1138.
22. Plante E, Lachance D, Drolet MC, Roussel E, Couet J, and Arsenault M (2005) Dobutamine stress echocardiography in healthy adult male rats. Cardiovasc Ultrasound 3:34-40.
23. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, and Vaziri ND (2006) Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 55:928-934.
24. Roberts CK, Vaziri ND, and Barnard RJ (2001) Protective effects of estrogen on gender-specific development of diet-induced hypertension. J Appl Physiol 91:2005-2009.
25. Ruetten H, Dimmeler S, Gehring D, Ihling C, and Zeiher AM (2005) Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 66:444-453.
26. Ruiz-Ortega M, Roriguez-Vita J, Sanchez-Lopez E, Carvajal G, and Egido J (2007) TGF-β signaling in vascular fibrosis. Cardiovasc Res 74:196-206.
27. Vachharajani V and Vital S (2006) Obesity and sepsis. J Intensive Care Med 21:287-295.
28. Van Gaal LF, Mertens IL, and deBlock CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875-880.
29. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, MD, and Förstermann U (2002) Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106:1652-1658.
30. Wang S, Wang X, Yan J, Xie X, Fan F, Zhou X, Han L, and Chen J (2007) Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: Correlated with NO-cGMP signaling pathway. Eur J Pharmacol 567:26-35.
31. Yamato M, Shiba T, Yoshida M, Ide T, Seri N, Kudou W, Kinugawa S, and Tsutsui H (2007) Fatty acids increase the circulating levels of oxidative stress factors in mice with diet-induced obesity via redox changes of albumin. FEBS J 274:3855-3863.
32. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL, and Termine JD (1996) Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 137:2075-2084.
33. Zaman AK, Fujii S, Goto D, Furumoto T, Mishima T, Nakai Y, Dong J, Imagawa S, Sobel BE, and Kitabatake A (2004) Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 37:525-535.